Review Article

The Emerging Role of Complement Lectin Pathway in Trypanosomatids: Molecular Bases in Activation, Genetic Deficiencies, Susceptibility to Infection, and Complement System-Based Therapeutics

Table 2

Complement system-based therapeutics. The clinical situation, principle of anticomplement therapy, and complement-based treatment are detailed.

Complement Deficiencies
Complement pathways involved Protein Associated geneComplications
AlternativeLectinClassical

Activation
Recognition protein

X MBLMBL2Infection in immunocompromised patient
XH-ficolinFCN3Immune deficiency,
necrotizing enterocolitis
X C1qC1QA, C1QB, C1QCSLE-like syndrome, recurrent
bacterial infections
X
MASP-2MASP-2Immune deficiency
X C1r/sC1R, C1SSLE-like syndrome, recurrent bacterial infections
XX C2C2Autoimmune disease
XFactor D CFDMeningococcal and encapsulated bacterial infections
XFactor ICFIEncapsulated bacterial infections

Common Pathways
Structural protein

XXX C3C3Bacterial infections, SLE-like syndrome
XXX C4C4A, C4BSLE- like syndrome, encapsulated bacterial infections
XXX C5C5Meningococcal infection
XXXC6C6Meningococcal infection
XXXC7C7Meningococcal infection
XXXC8C8A, C8B, C8GMeningococcal infection
XXX C9C9Meningococcal infection

Regulatory proteins
Control protein as

XProperdinCFPMeningococcal infection
Factor HCFHHemolytic uremic syndrome (HUS), dense deposit disease
CD11a (LFA-1), CD11b (CR3), CD11c (CR4)/CD18’ ITGAL, ITGAM, ITGAX, ITGB2Leucocyte adhesion deficiency type I ( LAD I)
CD46 (MCP)CD46Atypical hemolytic uremic syndrome (aHUS)